Compare SHIM & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHIM | SGMO |
|---|---|---|
| Founded | 1990 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.8M | 141.2M |
| IPO Year | 2023 | 2000 |
| Metric | SHIM | SGMO |
|---|---|---|
| Price | $3.22 | $0.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 94.5K | ★ 4.4M |
| Earning Date | 03-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.95 | 66.89 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $492,844,000.00 | $36,567,000.00 |
| Revenue This Year | $13.99 | $4.79 |
| Revenue Next Year | $6.94 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.63 | ★ 88.60 |
| 52 Week Low | $1.30 | $0.32 |
| 52 Week High | $4.47 | $0.84 |
| Indicator | SHIM | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 46.91 | 36.64 |
| Support Level | $2.54 | N/A |
| Resistance Level | $3.50 | $0.55 |
| Average True Range (ATR) | 0.40 | 0.03 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 59.49 | 4.91 |
Shimmick Corp is a provider of water and other critical infrastructure solutions nationwide. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure, including desalination plants. In water resources projects company builds, expands, and improves water storage and conveyance, dams, levees, flood control systems, pump stations, and coastal protection. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains its nation's critical infrastructure, including mass transit, bridges, and military infrastructure.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.